Research Posts on Medivizor
Navigation Menu

Research Posts on Medivizor

Is targeted therapy better at treating advanced NSCLC than current chemotherapy treatment?

Posted by on Apr 21, 2018 in Lung cancer | 0 comments

In a nutshell This study examined the effectiveness of the targeted therapy drug nivolumab (Opdivo) at treating advanced non-small-cell lung cancer, particularly for patients with cancer that has spread to the liver. The authors concluded that nivolumab led to an improved overall survival compared to chemotherapy for these patients. Some background...

Read More

How does a low-carbohydrate diet compare to a high-carbohydrate diet for the management of Type 2 diabetes?

Posted by on Apr 21, 2018 in Diabetes mellitus | 0 comments

In a nutshell This study compared the effects of a low-carbohydrate versus a high-carbohydrate diet on glycemic control and heart disease risk in obese adults with type 2 diabetes. This study concluded that both diets helped reduce body weight, HbA1c levels, and fasting blood glucose levels. However, the low-carbohydrate diet led to greater...

Read More

Salt intake and hypertension: could other dietary factors be influencing this relationship?

Posted by on Apr 20, 2018 in Hypertension | 0 comments

In a nutshell This study investigated the effects of dietary factors on the relationship between salt intake and hypertension. The study concluded that the association between salt intake and hypertension is not influenced by any other dietary factor. Some background Managing hypertension (high blood pressure) can be achieved using a number...

Read More

A review on new therapies to treat metastatic melanoma

Posted by on Apr 20, 2018 in Melanoma | 0 comments

In a nutshell This study reviewed other studies about different treatments for metastatic (spread to other parts of the body) melanoma. Researchers suggested that targeted therapy improves overall survival of these patients when compared to chemotherapy. Some background Melanoma is the most dangerous common skin cancer. 70 to 80% of patients are...

Read More

What are the long-term outcomes for HL patients who experience treatment failure after an autologous stem cell transplant?

Posted by on Apr 18, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study analyzed the survival outcomes of Hodgkin’s lymphoma (HL) patients who experience treatment failure after high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (autoSCT). This study concluded that a second stem cell transplant with or without brentuximab vedotin (Adcetris) may lead to better...

Read More

Is rituximab/bendamustine safer and more effective than R-CHOP in patients with grade 3A follicular lymphoma?

Posted by on Apr 18, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of the R-B (rituximab, bendamustine) regimen versus the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen in patients with grade 3A follicular lymphoma (FL3A). This study concluded that R-B is better tolerated and more effective than R-CHOP, making it a...

Read More

Risk of adverse events in new versus conventional treatment for multiple myeloma

Posted by on Apr 18, 2018 in Multiple Myeloma | 0 comments

In a nutshell This paper studied the risk of adverse events in patients who receive treatment for multiple myeloma. The use of new drugs increased the risk of low blood count, peripheral neuropathy and blood clots. Some background Multiple myeloma is a cancer of the plasma cells (type of white blood cell). Multiple myeloma can be treated with drugs...

Read More

A new treatment combination for patients with relapsed/refractory chronic lymphocytic leukemia

Posted by on Apr 18, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of venetoclax (Venclexta) and rituximab (Rituxan) treatment in patients with relapsed/refractory chronic lymphocytic leukemia. This study concluded that venetoclax-rituximab treatment was effective for these patients.     Some background Chronic lymphocytic leukemia...

Read More